ArticleNature communications2019
Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 52 citations in OpenAlex.
- The dual immune landscape of homologous recombination-deficient tumors: mechanisms and therapeutic implications.Cancer metastasis reviews · 2026Review
- Mouse genetic mosaic model for basal-like breast cancer reveals disruption of basal-myoepithelial architecture at premalignancy.Research square · 2026Article
- A multi-scale biological network framework for discovering MiRNA-Disease associations.Frontiers in bioinformatics · 2026Article
- Gap junction communication regulates luminal-myoepithelial crosstalk and cell differentiation in a bilayered human mammary epithelial cell model.Biology methods & protocols · 2026Article
- Healthy BRCA1/2 mutation carriers exhibit a pre-CAF signature and altered epithelial marker expression in breast tissue.Scientific reports · 2025Article
- DCIS Progression and the Tumor Microenvironment: Molecular Insights and Prognostic Challenges.Cancers · 2025Review
- Salivary Gland Tissue Recombination Can Modify Cell Fate.Journal of dental research · 2024Article
- Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance.Signal transduction and targeted therapy · 2024Review
- Article
- Mechanosensitive TRPV4 channel guides maturation and organization of the bilayered mammary epithelium.Scientific reports · 2024Article
- Spatial Transcriptomics Suggests That Alterations Occur in the Preneoplastic Breast Microenvironment of BRCA1/2 Mutation Carriers.Molecular cancer research : MCR · 2024Article
- BRCA1 the Versatile Defender: Molecular to Environmental Perspectives.International journal of molecular sciences · 2023Review
- A transcriptional response to replication stress selectively expands a subset of Brca2-mutant mammary epithelial cells.Nature communications · 2023Article
- Neurotrophin signaling is a central mechanism of salivary dysfunction after irradiation that disrupts myoepithelial cells.NPJ Regenerative medicine · 2023Article
- BRCA1 deficiency in mature CD8Journal for immunotherapy of cancer · 2023Article
- KLF4 loss in hepatocellular carcinoma: Improving prognostic prediction and correlating immune infiltrates.Frontiers in genetics · 2023Article
- ΔNp63/p73 drive metastatic colonization by controlling a regenerative epithelial stem cell program in quasi-mesenchymal cancer stem cells.Developmental cell · 2022Article
- Re-evaluation of the myoepithelial cells roles in the breast cancer progression.Cancer cell international · 2022Review
- Article
- Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
48 authors at 17 institutions in 4 countries.
Lina DingDepartment of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.
Ying SuDepartment of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.
Anne FasslDepartment of Cancer Biology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.
Kunihiko HinoharaDepartment of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.
Xintao QiuCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
Nicholas W HarperDepartment of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.
Sung Jin HuhDepartment of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.
Noga Bloushtain-QimronDepartment of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.
Bojana JovanovićDepartment of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.
Muhammad EkramDepartment of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.
Xiaoyuan ZiDepartment of Biomedical Engineering, Yale University, New Haven, CT, 06511, USA.ORCID http://orcid.org/0000-0002-2374-9001
William C HinesLawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA.
Maša AlečkovićDepartment of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0001-5653-8502
Carlos Gil Del AlcazarDepartment of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.
Ryan J CaulfieldLurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.
Dennis M BonalLurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0002-7805-1209
Quang-De NguyenLurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.
Vanessa F MerinoJohns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Sibgat ChoudhuryDepartment of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.
Gabrielle EthingtonBaylor-Charles A. Sammons Cancer Center, Dallas, TX, 75246, USA.
Laura PanosBaylor-Charles A. Sammons Cancer Center, Dallas, TX, 75246, USA.
Michael GrantBaylor-Charles A. Sammons Cancer Center, Dallas, TX, 75246, USA.
William HerlihyBaylor-Charles A. Sammons Cancer Center, Dallas, TX, 75246, USA.
Alfred AuUniversity of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, 94143, USA.
Gedge D RossonJohns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Pedram ArganiJohns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Andrea L RichardsonDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Deborah DillonDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
D Craig AllredDepartment of Pathology, Washington University School of Medicine, St. Louis, MO, 63110, USA.
Kirsten BabskiSutter Roseville Medical Center, Roseville, CA, 95661, USA.
Elizabeth Min Hui KimSutter Roseville Medical Center, Roseville, CA, 95661, USA.
Charles H McDonnellSutter Roseville Medical Center, Roseville, CA, 95661, USA.
Jon WagnerSutter Roseville Medical Center, Roseville, CA, 95661, USA.
Ron RowberrySutter Roseville Medical Center, Roseville, CA, 95661, USA.
Kristie BobolisSutter Roseville Medical Center, Roseville, CA, 95661, USA.
Celina G KleerDepartment of Pathology, University of Michigan, Ann Arbor, MI, 48109, USA.
E Shelley HwangUniversity of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, 94143, USA.
Joanne L BlumBaylor-Charles A. Sammons Cancer Center, Dallas, TX, 75246, USA.
Simona CristeaDepartment of Data Science, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.
Piotr SicinskiDepartment of Cancer Biology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0002-8859-5234
Rong FanDepartment of Biomedical Engineering, Yale University, New Haven, CT, 06511, USA.ORCID http://orcid.org/0000-0001-7805-8059
Henry W LongDepartment of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.ORCID http://orcid.org/0000-0001-6849-6629
Saraswati SukumarJohns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
So Yeon ParkDepartment of Pathology, Seoul National University College of Medicine, Seoul, Korea.
Judy E GarberDepartment of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA.
Mina BissellLawrence Berkeley National Laboratory, Berkeley, CA, 94720, USA.ORCID http://orcid.org/0000-0001-5841-4423
Jun YaoMD Anderson Cancer Center, Houston, TX, 77030, USA.
Kornelia PolyakDepartment of Medical Oncology, Dana-Farber Cancer Institute Boston, Boston, MA, 02215, USA. Kornelia_Polyak@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-5964-0382
Brigham and Women's Hospital · USDana-Farber Cancer Institute · USSutter Roseville Medical Center · USTexas Oncology · USJohns Hopkins University · USHarvard University · USLawrence Berkeley National Laboratory · USBoston University · USCancer Treatment Centers of America · USDuke University · USSecond Military Medical University · CNSeoul National University · KRThe University of Texas MD Anderson Cancer Center · USUniversity of California, San Francisco · USUniversity of Michigan · USWashington University in St. Louis · USYale University · US
Funding
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8MUse of Organotypic and Mammary Gland Models to Investigate the Outcomes of ClonalP01CA080111 · NCI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI DILLON, DEBORAH · 1999 to 2018
$36.0MTargeting intratumor heterogeneity in breast cancerR35CA197623 · NCI · DANA-FARBER CANCER INST · PI KORNELIA POLYAK · 2015 to 2026
$12.4MDefinition of the Microenvironment in Breast CancerR01CA064786 · NCI · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI BISSELL, MINA · 1995 to 2020
$6.1MRole of EZH2 in Breast Cancer ProgressionR01CA107469 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Celina G Kleer · 2005 to 2026
$5.9MRole of CCN6 (WISP3) in the Progression and Metastasis of Breast Cancer.R01CA125577 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Celina G Kleer · 2008 to 2026
$5.5MMyoepithelial cell differentiation defects in ductal carcinoma in situ (DCIS)U01CA143233 · NCI · DANA-FARBER CANCER INST · PI BISSELL, MINA, POLLARD, JEFFREY W. · 2009 to 2013
$2.5MNovel functions of D-type and E-type cyclins in normal and in cancer cellsR01CA202634 · NCI · DANA-FARBER CANCER INST · PI SICINSKI, PETER · 2016 to 2020
$2.1MNCI NIH HHS P01 CA080111NCI NIH HHS P30 CA014236NCI NIH HHS R01 CA064786NCI NIH HHS R01 CA107469NCI NIH HHS R01 CA125577NCI NIH HHS R01 CA202634NCI NIH HHS R35 CA197623NCI NIH HHS U01 CA143233
Abstract
Myoepithelial cells play key roles in normal mammary gland development and in limiting pre-invasive to invasive breast tumor progression, yet their differentiation and perturbation in ductal carcinoma in situ (DCIS) are poorly understood. Here, we investigated myoepithelial cells in normal breast tissues of BRCA1 and BRCA2 germline mutation carriers and in non-carrier controls, and in sporadic DCIS. We found that in the normal breast of non-carriers, myoepithelial cells frequently co-express the p63 and TCF7 transcription factors and that p63 and TCF7 show overlapping chromatin peaks associated with differentiated myoepithelium-specific genes. In contrast, in normal breast tissues of BRCA1 mutation carriers the frequency of p63
Indexed as
AnimalsBRCA1 ProteinBRCA2 ProteinCarcinoma, Ductal, BreastCell Line, TumorCell ProliferationFemaleFluorescent Antibody TechniqueGerm-Line MutationHumansImmunohistochemistryMiceMutationT Cell Transcription Factor 1Transcription FactorsTumor Suppressor ProteinsBRCA1 ProteinBRCA2 ProteinT Cell Transcription Factor 1TCF7 protein, humanTP63 protein, humanTranscription FactorsTumor Suppressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.